DMAC (DiaMedica Therapeutics) PS Ratio: (As of Jul. 02, 2026)


DMAC DiaMedica Therapeutics Inc DMAC
31 GF Score
Price $7.45
! 1 Warning Sign
View Full Analysis

What is DiaMedica Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, DiaMedica Therapeutics's share price is $7.445. DiaMedica Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00. Hence, DiaMedica Therapeutics's PS Ratio for today is .

The historical rank and industry rank for DiaMedica Therapeutics's PS Ratio or its related term are showing as below:

During the past 13 years, DiaMedica Therapeutics's highest PS Ratio was 162.97. The lowest was 17.66. And the median was 59.69.

DMAC's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.53
* Ranked among companies with meaningful PS Ratio only.

DiaMedica Therapeutics's Revenue per Sharefor the three months ended in Mar. 2026 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00.

During the past 13 years, DiaMedica Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 269.00% per year. The lowest was 269.00% per year. And the median was 269.00% per year.

Back to Basics: PS Ratio


DiaMedica Therapeutics  (NAS:DMAC) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


DiaMedica Therapeutics PS Ratio Related Terms


DiaMedica Therapeutics PS Ratio Historical Data

* Premium members only.

The historical data trend for DiaMedica Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DiaMedica Therapeutics PS Ratio Chart

DiaMedica Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

DiaMedica Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

DMAC vs PRLD, RCKT, TENX: PS Ratio Comparison

For the Biotechnology subindustry, DiaMedica Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DiaMedica Therapeutics PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DiaMedica Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where DiaMedica Therapeutics's PS Ratio falls into.


DMAC
31GF Score
DiaMedica Therapeutics Inc DMAC
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DiaMedica Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

DiaMedica Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=7.445/0
=

DiaMedica Therapeutics's Share Price of today is $7.445.
DiaMedica Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


DiaMedica Therapeutics Business Description

Address 301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
31GF Score

Get the complete analysis for DMAC

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.45
Price